Bimatoprost 300micrograms/ml eye drops 0.4ml unit dose preservative free
Requires a prescription from a doctor or prescriber
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Bimatoprost
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Bimatoprost
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Bimatoprost
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
7 branded products available
MHRA licensed products
View all licensed products for Bimatoprost on the MHRA register
Lumigan 300micrograms/ml eye drops 0.4ml unit dose
Bimatoprost 300micrograms/ml eye drops 0.4ml unit dose preservative free
Bimatoprost 300micrograms/ml eye drops 0.4ml unit dose preservative free
Bimatoprost 300micrograms/ml eye drops 0.4ml unit dose preservative free
Bimatoprost 300micrograms/ml eye drops 0.4ml unit dose preservative free
Bimatoprost 300micrograms/ml eye drops 0.4ml unit dose preservative free
Bimatoprost 300micrograms/ml eye drops 0.4ml unit dose preservative free
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 12 · Randomised trials: 22 · 2001–2026
Showing the 50 most relevant studies, sorted by most relevant.
Robert Noecker, Monte S. Dirks, Neil T Choplin, et al.
American Journal of Ophthalmology, 2002
- Bimatoprost
- Latanoprost
- Amides
Peng J, Huang W, Duan J
2025
ObjectiveTo evaluate and compare the effectiveness and safety of latanoprost, bimatoprost, travoprost, and tafluprost in lowering intraocular pressure (IOP) in individuals with glaucoma or ocular hypertension.MethodsWe searched PubMed, Embase, Web of Science, and the Cochrane Library for randomized controlled trials (RCTs) published up to April 2025 comparing latanoprost, bimatoprost, travoprost, and tafluprost in adults with glaucoma or ocular hypertension. Primary outcomes were IOP reduction and conjunctival hyperemia. We assessed study quality using the Cochrane Risk of Bias 2.0 tool. Evidence certainty was evaluated with the CINeMA framework. A Bayesian network meta-analysis was conducted in RStudio. This review is registered with PROSPERO (CRD420251034803).Results25 RCTs published between 2001 and 2024, involving 4,045 participants, were included. All studies compared monotherapy with latanoprost, bimatoprost, travoprost, or tafluprost. Among these, bimatoprost showed the most effective reduction in intraocular pressure compared to latanoprost [mean difference (MD) 0.69; 95%confidence interval (CI) 0.28-1.1; SUCRA 95.6%; moderate confidence]. It also performed significantly better than travoprost (MD 0.64; 0.14-1.09; 39.2%; low confidence). No other comparisons showed statistically significant differences. Overall, the quality of evidence for this outcome ranged from low to moderate. In terms of safety, 16 trials, including 3,119 participants, reported on conjunctival hyperemia. Both bimatoprost [odds ratio (OR) 3.3; 2.5-4.5; 18.4%, high confidence] and travoprost (0.46; 0.33-0.63; 55%, high confidence) were associated with a higher risk of hyperemia compared to latanoprost. Bimatoprost also posed a significantly greater risk than travoprost (1.51; 1.06-2.16, high confidence).ConclusionBimatoprost provided the greatest IOP reduction but carried a higher risk of conjunctival hyperemia. Latanoprost and tafluprost offered balanced efficacy with better tolerability, making them suitable for patients with mild disease.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251034803.
Abstract licence: CC BY
Cherecheanu AP, Cornelis de Crom RMP, Baschet L, et al.
2026
King A, Sood S, Li MK
2025
Thomas R. Walters, Harvey Dubiner, Susan P. Carpenter, et al.
Survey of Ophthalmology, 2004
- Bimatoprost
- Latanoprost
- Amides
Hong-wei Liu
2020
L. Jay Katz, John Cohen, Amy L. Batoosingh, et al.
American Journal of Ophthalmology, 2010
- Bimatoprost
- Amides
- Antihypertensive Agents
Jin-Wei Cheng, Rui-Li Wei
Clinical Therapeutics, 2008
- Bimatoprost
- Latanoprost
- Amides
Mona Ali, Hala S A Hafiz, N. Ahmed, et al.
Journal of Cosmetic Dermatology, 2023
Francisco J Muñoz-negrete, F. Topouzis, Francesco Oddone, et al.
Journal of Glaucoma, 2024
- Ocular Hypertension
- Glaucoma, Open-Angle
- Antihypertensive Agents
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
7 found
Half-life
45 minutes
Mechanism
Bimatoprost imitates the effects of prostamides, specifically prostaglandin F2α.
Food interactions
None known
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.03%
Half-life
45 minutes
[L6877][L6892]
Protein binding
88%
[L6877][L6892]
Volume of distribution
0.67 L/kg
[L6877][L6898]
It penetrates the human cornea and sclera.
[L6898]
Metabolism
[L6913]
…
Elimination
67%
[L6877]
…
Clearance
1.5 L/h
[L6877][L6892]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.
[L6877]
Bimatoprost is also indicated to treat eyelash hypotrichosis.
[L6910]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1330 interactions
[L6877]
Other effects of this drug may include gradual changes in eyelid pigmentation, changes in iris pigmentation, changes in eyelash pigmentation, growth and thickness.[L6877] Patients should be informed of these possible effects, especially if this drug is only administered to one eye, which may noticeably change in appearance with bimatoprost treatment.[L6877]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L6877]
By 10 minutes, peak blood concentration was achieved.
Bimatoprost was not detectable at 1.5 hours after administration in most subjects. The maximum blood concentration in a study of 6 healthy volunteers was determined to be 12.2 ng/mL. Steady state was reached in the first week of dosing.
[L6877]
One drug label mentions that onset of decreased intraocular pressure occurs approximately 4 hours after the first administration and the peak effect occurs in the range of 8-12 hours.
Bimatoprost effects may last up to 24 hours.
[L6898]
[L6877][L6892]
[L6877][L6892]
[L6877][L6898]
It penetrates the human cornea and sclera.
[L6898]
[L6913]
Bimatoprost undergoes oxidation, N-deethylation, and glucuronidation after it is systemically absorbed, and this leads to the production of various metabolites.
[L6877]
In vitro studies show that CYP3A4 is an enzyme that participates in the metabolism of bimatoprost. Despite this, many enzymes and pathways metabolize bimatoprost, therefore, no significant drug-drug interactions are likely to occur.
[L6892]
Glucuronidated metabolites comprise most of the excreted drug product in the blood, urine, and feces in rats.
[L6892]
[L6877]
[L6877][L6892]
Proteins and enzymes this drug interacts with in the body
Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and isoform 5 are proposed to be a receptor for prostamides including the synthetic analog bimatoprost
Implicated the smooth muscle contractile response to PGE2 in various tissues
PMID:7883006 PMID:7981210 PMID:8117308 PMID:8135729 PMID:8307176
The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G(i) proteins, and to an elevation of intracellular calcium .
PMID:7883006 PMID:7981210 PMID:8117308 PMID:8135729
Required for normal development of fever in response to pyrinogens, including IL1B, prostaglandin E2 and bacterial lipopolysaccharide (LPS). Required for normal potentiation of platelet aggregation by prostaglandin E2, and thus plays a role in the regulation of blood coagulation. Required for increased HCO3(-) secretion in the duodenum in response to mucosal acidification, and thereby contributes to the protection of the mucosa against acid-induced ulceration.
Not required for normal kidney function, normal urine volume and osmolality (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC S01EE03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Bimatoprost
Additional database identifiers
Drugs Product Database (DPD)
12108
ChemSpider
4470565
BindingDB
220120
PDB
15M
Guide to Pharmacology
1958
ZINC
ZINC000004474405
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9600
GenAtlas
PTGFR
GeneCards
PTGFR
GenBank Gene Database
L24470
GenBank Protein Database
456564
Guide to Pharmacology
344
UniProt Accession
PF2R_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9593
GenAtlas
PTGER1
GeneCards
PTGER1
GenBank Gene Database
L22647
GenBank Protein Database
410209
Guide to Pharmacology
340
UniProt Accession
PE2R1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9595
GenAtlas
PTGER3
GeneCards
PTGER3
GenBank Gene Database
S69200
Guide to Pharmacology
342
UniProt Accession
PE2R3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2638
GenAtlas
CYP3A5
GeneCards
CYP3A5
GenBank Gene Database
J04813
GenBank Protein Database
181346
Guide to Pharmacology
1338
UniProt Accession
CP3A5_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72